abstract |
A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or deriva-tive thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabi-lizing effect at 0 to +10°C or in a liquid-frozen composition, for example between -10°C and -30°C or between -20°C and -23.5°C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human. |